Forget This Biotech Stock’s Rally Signals Fresh Jump
NovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
An overview of which total market fund performed best in 2024, with notes on expense, tracking error, and performance drivers.
28,518 articlesNovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
Exxon Mobil, Chevron and other producers climb to all-time stock valuations as geopolitical risk pushes energy prices...
A veteran figure in AI, nicknamed the 'godfather ai,' argues big tech prioritizes short-term profits over the endgame...
Geopolitical frictions with Iran are boosting energy and raw-material costs. A prominent downgrade underscores how th...
FHA delinquencies are climbing even as overall mortgage distress remains contained. Analysts warn this could become a...
USA Rare Earth is set to publish its Q1 2026 results after market close as investors await production updates and the...
Markets shift as the White House cools its push for rate cuts while Kevin Warsh faces inflation constraints. The 10-y...
When a major chip stock slips, it sparks questions about why the move happened and what it means for your plan. This ...
A 59-year-old faces a six-figure tax bill after an indirect IRA rollover violated the once-per-year rollover rule 59-...
SoftBank Group stock tumbled about 20% over the past five trading days as questions surrounding OpenAI funding and th...
Public disclosures show a former president engaged in a rapid trading spree in the first quarter, totaling 3,600 stoc...
A 62-year-old retiree faces a tax decision as SpaceX posts a 37% pop. The choice between a Roth IRA and a taxable bro...